 |
|
Compound has potential for new class of AIDS drugs
May 15, 2008ANN ARBOR, Mich.-Researchers have developed what they believe is the first new mechanism in nearly 20 years for inhibiting a common target used to treat all HIV patients, which could eventually lead to a new class of AIDS drugs.
Researchers at the University of Michigan used computer models to develop the inhibiting compound, and then confirmed in the lab that the compound does indeed inhibit HIV protease, which is an established target for AIDS treatment. The protease is necessary to replicate the virus, says Heather Carlson, U-M professor of medicinal chemistry and principal investigator of the study.
Carlson stresses this is a preliminary step, but still significant.
"It's very easy to make an inhibitor, (but) it's very hard to make a drug," said Carlson, who also has an appointment in chemistry. "This compound is too weak to work in the human body. The key is to find more compounds that will work by the same mechanism."
What's so exciting is how differently that mechanism works from the current drugs used to keep the HIV from maturing and replicating, she says. Current drugs called protease inhibitors work by debilitating the HIV-1 protease. This does the same, but in a different way, Carlson says.
A protease is an enzyme that clips apart proteins, and in the case of HIV drugs, when the HIV-1 protease is inhibited it cannot process the proteins required to assemble an active virus. In existing treatments, a larger molecule binds to the center of the protease, freezing it closed.
The new mechanism targets a different area of the HIV-1 protease, called the flap recognition pocket, and actually holds the protease open. Scientists knew the flaps opened and closed, but didn't know how to target that as a mechanism, Carlson says.
Carlson's group discovered that this flap, when held open by a very small molecule-half the size of the ones used in current drug treatments-also inhibits the protease.
In addition to a new class of drugs, the compound is key because smaller molecules have better drug-like properties and are absorbed much more easily.
"This new class of smaller molecules could have better drug properties (and) could get around current side effects," Carlson said. "HIV dosing regimes are really difficult. You have to take medicine several times in the day. Maybe you wouldn't have to do that with these smaller molecules because they would be absorbed differently."
Kelly Damm, a former student and now at Johnson & Johnson, initially had the idea to target the flaps in this new way, Carlson says.
"In a way, this works like a door jam. If you looked only at the door when it's shut, you'd not know you could put a jam in it," she said. "We saw a spot where we could block the closing event, but because everyone else was working with the closed form, they couldn't see it."
University of Michigan
"It's very easy to make an inhibitor, (but) it's very hard to make a drug," said Carlson, who also has an appointment in chemistry. "This compound is too weak to work in the human body. The key is to find more compounds that will work by the same mechanism."
What's so exciting is how differently that mechanism works from the current drugs used to keep the HIV from maturing and replicating, she says. Current drugs called protease inhibitors work by debilitating the HIV-1 protease. This does the same, but in a different way, Carlson says.
A protease is an enzyme that clips apart proteins, and in the case of HIV drugs, when the HIV-1 protease is inhibited it cannot process the proteins required to assemble an active virus. In existing treatments, a larger molecule binds to the center of the protease, freezing it closed.
The new mechanism targets a different area of the HIV-1 protease, called the flap recognition pocket, and actually holds the protease open. Scientists knew the flaps opened and closed, but didn't know how to target that as a mechanism, Carlson says.
Carlson's group discovered that this flap, when held open by a very small molecule-half the size of the ones used in current drug treatments-also inhibits the protease.
In addition to a new class of drugs, the compound is key because smaller molecules have better drug-like properties and are absorbed much more easily.
"This new class of smaller molecules could have better drug properties (and) could get around current side effects," Carlson said. "HIV dosing regimes are really difficult. You have to take medicine several times in the day. Maybe you wouldn't have to do that with these smaller molecules because they would be absorbed differently."
Kelly Damm, a former student and now at Johnson & Johnson, initially had the idea to target the flaps in this new way, Carlson says.
"In a way, this works like a door jam. If you looked only at the door when it's shut, you'd not know you could put a jam in it," she said. "We saw a spot where we could block the closing event, but because everyone else was working with the closed form, they couldn't see it."
University of Michigan
Protease Current Events and Protease News RSSNo-entry zones for AIDS virus
The AIDS virus inserts its genetic material into the genome of the infected cell. Scientists of the German Cancer Research Center have now shown for the first time that the virus almost entirely spares particular sites in the human genetic material in this process. This finding may be useful for developing new, specific AIDS drugs.
Alternatively spliced tissue factor identified as promising new biomarker for aggressive cancers
A recently discovered form of the protein that triggers blood clotting may play a key role in the molecular mechanisms leading to the growth of certain metastatic cancers, according to new research reported by an international team of scientists.
Super sticky barnacle glue cures like blood clots
Barnacles are a big problem for boats. Adhering to the undersides of vessels, carpets of the crustaceans can increase fuel consumption by as much as 25%.
Major discovery opens door to leishmania treatment
Leishmania is a deadly parasitic disease that affects over 12 million people worldwide, with more than 2 million new cases reported every year.
How Proteins Talk to Each Other
Investigators at Burnham Institute for Medical Research (Burnham) have identified novel cleavage sites for the enzyme caspase-3 (an enzyme that proteolytically cleaves target proteins).
Weighing costs, benefits of HIV treatments
Prevention versus treatment? Cost versus efficacy? So go two of the dilemmas looming over Dartmouth's Paul E. Palumbo, M.D., and his fellow researchers in the race to fight HIV and other infectious diseases in the developing world - especially among women and their young children.
Yes-associated protein: Early diagnosis of gastric carcinoma
Yes-associated protein (YAP) is a type of cellular adaptor protein and transcriptional co-activator.
Researchers restore missing protein in rare genetic brain disorder
UCSF researchers have successfully used protease inhibitors to restore to normal levels a key protein involved in early brain development. Reduced levels of that protein have been shown to cause the rare brain disorder lissencephaly, which is characterized by brain malformations, seizures, severe mental retardation and very early death in human infants.
Protein plays unexpected role protecting chromosome tips
A protein specialist that opens the genomic door for DNA repair and gene expression also turns out to be a multi-tasking workhorse that protects the tips of chromosomes and dabbles in a protein-destruction complex, a team lead by researchers at The University of Texas M. D. Anderson Cancer Center reports in the Aug. 13 edition of Molecular Cell.
Current hepatitis C treatments work equally well, UT Southwestern and national researchers report
The three treatment combinations for clearing the most common form of the hepatitis C virus work equally well with similar side effects, UT Southwestern Medical Center researchers and their colleagues in 13 other institutions have found.
More Protease Current Events and Protease News Articles
 |
Houston Nutraceuticals, Houston Enzymes Peptizyde Multiple Protease 90 Vegetable Capsules by Houston Nutraceuticals, Houston Enzymes Peptizyde (pronounced "Pep-ta-zyde") is a combination of three different proteolytic enzymes isolated from plant sources. Each enzyme has a unique set of peptide bonds it prefers to break, so the combination of these enzymes allows much more efficient means of quickly and thoroughly breaking down (hydrolyzing) proteins to its smaller components. The enzymes in Peptizyde work only on food proteins, not carbohydrates, fats, or other compounds, and do not interfere with medications or other supplements (unless they are also proteins, which is extremely unlikely). Peptizyde may be used in combination with other enzyme products. Peptizyde supplements the "normal" hydrolysis of casein, gluten, and other food proteins such that the exorphin peptides are not produced because the specific cleavage... |
 |
Digestive Enzymes 500 mg, 240 Caps by Source Naturals Digestive Aid Enzyme Supplement Each capsule contains 500 mg of an all-vegetarian, broad spectrum blend of digestive enzymes. |
 |
Protease Inhibitors in AIDS Therapy (Infectious Disease and Therapy) by Richard C. Ogden (Author), Charles Flexner (Author) Agouron Pharmaceuticals, Inc., San Diego, CA. Reviews the impact of advances in recombinant DNA technology for understanding and treating HIV and AIDS. Highlights a variety of stories of pharmaceutical companies and biotechnology start-up firms. Reports on efforts to manage antiviral resistance in the clinic. |
 |
PROTEASE PLUS (90) by Nature's Sunshine Herbal Products Protease Plus provides supplemental protease enzymes that break down proteins into smaller proteins and amino acids, maximizing digestion. As we grow older, our bodies produce fewer enzymes. When a suboptimal level of protease enzyme exists, undigested proteins can pass through the intestinal tract and remain undigested. These have been linked to effects on overall health and vitality. Protease Plus may support immunity by possibly activating macrophages and natural killer cells. NSP's formula provides a full spectrum of plant-derived trace minerals, which help activate enzymes. Each capsule of NSP Protease Plus contains 60,000 HUT protease in a base of beet root fiber and plant-sourced trace mineral concentrate. Take 1 capsule with a meal three times daily for protein digestion.... |
 |
PROTEASE, HIGH POTENCY (60) by Nature's Sunshine Herbal Products Protease, High-Potency delivers 180,000 HUT's protease with a full spectrum of plant-derived trace minerals. Enjoy the same benefits of three Protease Plus capsules in one capsule of High-Potency Protease. Take 1 capsule between meals up to three times daily. |
 |
Digestive Enzymes for Bloated Stomach with Ginger Root, Clove, Fennel Seed, Peppermint, Acid Stable Protease by Oleda These DIGESTIVE ENZYMES are for abdominal bloating, gas, belching, indigestion, fatigue, irregularity, constipation, lack of energy, irritable bowels, flatulence, heartburn, tiredness, and other digestive problems. |
 |
Prozyme (454 gm) by Prozyme Products Ltd The enhanced bioavailability and superior assimilation of the vitamins, minerals, essential fatty acids, and other vital nutrients as a result of adding PROZYME to the food, is beneficial for pets of all ages, especially older ones; particularly those experiencing problems which benefit from increased nutritional absorption. Daily dosage: ΒΌ tsp. per cup of food. For initial use, begin by providing a small quantity and gradually increase the dosage to the appropriate amount. Dosages should be doubled for companion animals eight years of age or older. Store in a dry area out of extreme heat and direct sunlight. |
 |
Pancreatin 4x 500mg 100 Capsules by NOW Foods Pancreatin is a preparation of porcine pancreatic enzymes. Pancreatin naturally contains protease (protein digesting), amylase (carbohydrate digesting), and lipase (fat digesting) enzymes. |
 |
Mechanisms of Protease Action by Laszlo Polgar (Author) A uniform treatment of the four protease groups and a discussion of the differences and similarities in their action is presented in this important new publication. Serine, cysteine, aspartate, and zinc proteases are systematically discussed by nomenclature, evolution, specificity and their regulatory role. The chemistry of the peptide bond, including the catalysis of ester and peptide hydrolyses, is explained.For each protease group the emphasis is placed on the structure and function. Kinetics, enzyme modifications, isotope effects, subzero temperature investigations, nuclear magnetic resonance measurements, X-ray diffraction data, binding of transition-state analogs, zymogen activation, and site-specific mutagenesis are combined to rationalize the action of proteases. Both natural... |
 |
Charlie Rose with Forrest Sawyer; Ellen Barkin; Larry Kramer (January 18, 1995) ABC News journalist Forrest Sawyer talks about his new program Day One, his ascent as a journalist, and the competitive world of network television. Then, Ellen Barkin discusses her new film Bad Company, co-starring Laurence Fishburne, her background, and her long and prolific career as an actor. Finally, Larry Kramer on AIDS and the American response to the epidemic. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
| © 2009 BrightSurf.com |